BGB-53038

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameBGB-53038
Drug Alias NameBGB-53038
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursNeoplasm Metastasis +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[6
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaSolid tumoursNeoplasm Metastasis +[10
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A